Pharmacokinetics, Efficacy and Safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in Previously Treated Patients with Severe Hemophilia A: Results of a Prospective, Multicenter, Open-Label Phase III Study

Publisher： Karger

E-ISSN： 1421-9662|119|2|89-97

ISSN： 0001-5792

Source： Acta Haematologica, Vol.119, Iss.2, 2008-02, pp. : 89-97

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

P057: Efficacy and safety of Peginterferon alfa‐2b (40 kD, Y Shape) (Pegberon) in HBeAg‐ positive CHB patients — a phase III, randomized, multicenter, positive‐controlled, open‐label clinical study

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 48-48

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics of Human Tick-borne Encephalitis Virus Antibody Levels after Injection with Human Tick-borne Encephalitis Immunoglobulin, Solvent/Detergent Treated, FSME-BULIN S/D in Healthy Volunteers

By Adner Nils   Leibl Heinz   Enzersberger Oskar   Kirgios Mimika   Wahlberg Thomas  

Scandinavian Journal of Infectious Diseases, Vol. 33, Iss. 11, 2001-11 ,pp. : 843-847

Informa Healthcare

Access to resources Recommend Favorite

Switching STudy of Kidney TRansplant PAtients with Tremor to LCP‐TacrO (STRATO): an open‐label, multicenter, prospective phase 3b study

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 9, 2015-09 ,pp. : 796-805

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 994-1002

John Wiley & Sons Inc

Access to resources Recommend Favorite